First Approval of Semaglutide for MASH in India: A Paradigm Shift in MASLD Management? [0.03%]
司美格鲁肽在印度用于MASLD治疗的首次批准：这会是MASLD管理方式的一次变革吗？
Devaraj Ezhilarasan,Muthusethupathi Sharmila
Devaraj Ezhilarasan
Asfar S Azmi,Philip A Philip
Asfar S Azmi
Drug type contributions to pharmaceutical innovation: A USA-China comparative analysis [0.03%]
中美医药创新药物类型对比分析
Michael S Kinch,Aayan Alwani,Tyler Schwartz et al.
Michael S Kinch et al.
An analysis of experimental medicines entering clinical trials from 2000 to 2024 reveals divergent patterns of development activity between the USA and China. Whereas China's ascent was consistent in the most common therapeutic category: sm...
Covalent small-molecule RNA targeting in Alzheimer's disease: computational strategies, challenges and opportunities [0.03%]
阿尔茨海默病中RNA的小分子共价靶向：计算策略、挑战与机遇
Vanktesh Kumar,Stalin Arulsamy,Shivank Sharma et al.
Vanktesh Kumar et al.
RNA dysfunction is increasingly recognized as an upstream driver of Alzheimer's disease pathology, and covalent small molecules that engage pathogenic RNA structures are emerging as a therapeutic strategy. In addition to its role as a templ...
Can agentic AI dent Eroom's Law? Large reasoning models across the drug discovery and development pipeline [0.03%]
代理式AI能否缓解Eroom定律？大型推理模型在药物发现和开发全流程中的应用
Sheraz Khan,John G Samuelsson,Xuemei Cai et al.
Sheraz Khan et al.
Productivity in pharmaceutical R&D continues to fall despite deeper biological insight and steady gains in clinical development operations - a phenomenon termed Eroom's Law. Agentic AI workflows powered by reasoning-trained large language m...
Does Australia's Reformed R&D Tax Incentive Scheme Spur or Stifle Innovation? [0.03%]
澳大利亚改革研发税收优惠政策会激励还是阻碍创新？
Levon M Khachigian,Lynne Pezzullo
Levon M Khachigian
The 2026-27 Federal Budget introduced changes to Australia's Research and Development Tax Incentive (RDTI) and capital gains tax (CGT) framework. The Government argues the reforms will better support young, high-growth companies. However, l...
Pedro Filho Noronha Souza
Pedro Filho Noronha Souza
Jie-Ning Li,Ching-Hung Lin,Ming-Yang Wang et al.
Jie-Ning Li et al.
Tumor hypoxia not only promotes cancer progression, therapy resistance and immune escape, but it also creates therapeutically exploitable vulnerabilities. This review focuses on strategies that target hypoxic tumor adaptation, including hyp...
Degraders of histone lysine methyltransferases: Progress, challenges, and opportunities [0.03%]
组蛋白赖氨酸甲基转移酶降解剂：进展、挑战与机遇
Mengling Yang,Qiangsheng Zhang,Jing Yang et al.
Mengling Yang et al.
Histone lysine methyltransferases (HKMTs) are a class of enzymes capable of catalyzing the methylation modification of lysine residues on histones. Members of the lysine methyltransferase family, such as EZH2, G9a, DOT1L, NSD2, NSD3, and AS...
Single-cell and spatial transcriptomic insights into fibrotic mechanisms and therapeutic opportunities [0.03%]
单细胞和空间转录组学揭示纤维化机制和治疗机会
Jia Mi,Kaixin Su,Rifu Wang et al.
Jia Mi et al.
Fibrosis is a conserved response to chronic injury in which excessive extracellular matrix (ECM) deposition disrupts tissue architecture and organ function. Single-cell RNA sequencing and spatial transcriptomics now show that fibrosis is dr...